Core Viewpoint - The company plans to invest 1.485 billion yuan in a health consumer goods industrial park project, focusing on the production of health-related products and logistics facilities [1] Group 1: Investment Details - The total investment amounts to 1.485 billion yuan, which includes 1.421 billion yuan for fixed asset investment and 64 million yuan for working capital [1] - The project will cover a total land area of 406,800 square meters and is expected to take approximately 22 months to complete [1] Group 2: Project Purpose - The industrial park will be used for the production of food and medicine integration products, health supplements, and functional foods [1] - Facilities will include storage and logistics, quality inspection center, new product incubation center, e-commerce sorting, and finished drug warehousing [1]

东阿阿胶股份有限公司 内部审计制度 （2026 年 2 月 9 日 经公司第十一届董事会第十七次会议审议通过） 第一章 总则 第一条 为了规范东阿阿胶股份有限公司（以下简称"东阿阿胶" 或"公司"）及各子公司的内部审计工作，有效贯彻落实上级单位等 相关管理要求，不断规范经营行为、防范和降低经营风险、提升经营 效率和效果，实现高质量发展，根据《中华人民共和国审计法》《审 计署关于内部审计工作的规定》《关于深化中央企业内部审计监督工 作的实施意见》《中国内部审计准则》等法律法规规定，制定本制度。 第二条 本制度适用于东阿阿胶及下属公司（以下简称"各级单 位"）。 第三条 本制度所称内部审计，是指东阿阿胶内部独立、客观的 监督、评价和建议活动，通过运用系统、规范的方法，审查评价重大 决策部署、政策措施、监管要求落实、战略执行、法律法规遵循、经 济活动、风险管理、内部控制、财务收支、企业文化等情况，总结管 理实践，揭示问题和风险，提出改善建议，督促整改落实，推动公司 战略落地、规范经营、完善治理，实现高质量可持续发展。 第四条 内部审计的宗旨是保障战略、防范风险、创造价值。东 阿阿胶各级单位应当自觉配合内部审计机构， ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2026-06 东阿阿胶股份有限公司 关于投资建设健康消费品产业园项目的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、投资概述 为扎实落地东阿阿胶股份有限公司（以下简称"公司"或"东阿阿胶"）"1238" 发展战略，有效支撑健康消费品业务高质量发展，公司于 2026 年 2 月 9 日召开 第十一届董事会第十七次会议，审议通过了《关于投资建设健康消费品产业园项 目的议案》。 公司拟以 14.85 亿元（其中固定资产投资 14.21 亿元，铺底流动资金 0.64 亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、 功能性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电 商分拣及药品成品仓储等。公司董事会决议授权管理层具体推进落实该项目，包 括但不限于进一步完善规划设计、细化投资测算、建设施工，以及办理其他与本 投资事项相关的一切事宜。 1．项目名称：东阿阿胶健康消费品产业园建设项目 2．投资主体：东阿阿胶股份有限公司 3．建设地址：山东省聊城市东阿县经济开发区 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2026-05 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十七次 会议，于 2026 年 2 月 6 日以邮件方式发出会议通知。 2．本次董事会会议，于 2026 年 2 月 9 日以通讯表决方式召开。 3．会议应出席会议董事 9 人，实际出席会议董事 9 人。 第十一届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 东阿阿胶股份有限公司 4．本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 1．《关于调整董事会专门委员会委员的议案》 会议同意对公司第十一届董事会战略委员会、提名委员会、审计委员会及 薪酬与考核委员会组成人员进行补充调整，调整后的委员会成员名单如下： （1）董事会战略委员会 程杰（主任委员）、果德安、徐培清、王毅飞、孙金妮 （2）董事会提名委员会 果德安（主任委员）、文光伟、程翔林、程杰、王毅飞 （3）董事会审计委员会 文光伟（主 ...

Core Viewpoint - The appointment of Zhou Jianzhong as the new CEO of Kewang Pharmaceutical reflects the company's commitment to professionalizing its management team and modernizing its governance system, ensuring stability in its core management structure and continuity in strategic development [1][2]. Governance System Optimization - The change in the CEO position does not alter the stability of Kewang Pharmaceutical's core management team, as evidenced by adjustments in the board's specialized committees, which maintain strategic continuity and professionalism [2]. - The strategic committee now includes Chairman Guan Yuxiu, Guan Yi, and new CEO Zhou Jianzhong, while the compensation and assessment committee consists of Miao Jiajun, Zhao Yan, and Guan Yi [2][3]. - Zhou Jianzhong, with a strong background in the pharmaceutical industry, is well-suited for the company's current development stage, having held key management positions in several well-known pharmaceutical companies [3]. Strategic Development - Kewang Pharmaceutical is actively adapting to industry trends and deepening its strategic transformation, focusing on the health industry as a key growth area [4]. - The company aims to leverage its "Xiao Kewang" brand advantage to develop a multi-channel operational system, emphasizing both prescription and OTC pharmaceuticals alongside health products [4]. Brand and Market Position - The combined brand value of "Kewang" for adult health and "Xiao Kewang" for children's health exceeds 36.5 billion, with leading consumer recognition in the industry [5]. - The company has established a marketing network covering 8,000 hospitals and 450,000 retail terminals, forming strategic partnerships with 500 pharmaceutical distribution companies to support its health product expansion [5]. Product Development - Kewang Pharmaceutical holds over 1,000 drug approval numbers, with more than 500 in the medical insurance directory and nearly 300 in the basic drug directory, including around 30 exclusive varieties [6]. - The company plans to enhance research and development in core areas such as elderly care, children's health, and women's health, with several health products already in the approval process [6]. Management Upgrade and Future Outlook - The stable core management team and clear strategic layout provide a solid foundation for Kewang Pharmaceutical, with the professional management team expected to inject new vitality into the company's growth [7]. - The management upgrade reflects the company's strategic determination to adapt to industry changes and optimize its governance structure, positioning it for high-quality development driven by policy benefits and market demand [7].

Investment Rating - The report upgrades the investment rating for the pharmaceutical and biotechnology industry to "Recommended" [1][42]. Core Insights - The pharmaceutical sector has shown resilience, with a year-to-date return of 3.28%, outperforming the Shanghai Composite Index by 2.99 percentage points [9][23]. - The report highlights the continuous support from policies, particularly for the traditional Chinese medicine (TCM) sector, which is expected to see significant growth due to government initiatives aimed at enhancing the industry [15][17]. - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that domestic companies are gradually improving their innovation capabilities [42]. Summary by Sections Recent Performance - The Shanghai Composite Index fell by 1.33% while the pharmaceutical sector rose by 0.14%, ranking 15th among 31 primary sub-industries [14][23]. - Within the pharmaceutical sub-sectors, traditional Chinese medicine, medical services, and other segments showed varying performance, with traditional Chinese medicine increasing by 2.56% [14][23]. Policy Developments - On February 5, 2026, the Ministry of Industry and Information Technology and other departments released the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," focusing on enhancing the resilience and stability of the TCM supply chain [15][17]. - The plan aims to improve the quality and stable supply of TCM materials and products, which is crucial for the long-term development of the industry [15][17]. Market Dynamics - The report notes that the TCM sector is expected to experience a recovery in performance starting from mid-2025, with improved financial results anticipated in 2026 [9][17]. - The comprehensive index for TCM materials has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies in 2026 [9][17]. Valuation Metrics - As of February 6, 2026, the pharmaceutical sector's valuation stands at 33.3 times PE, with a premium of 32% compared to the overall A-share market (excluding financials) [24]. - The TTM valuation is at 29.4 times PE, below the historical average of 34.9 times PE, indicating potential for growth [24]. Key Companies to Watch - The report suggests focusing on companies such as Aidi Pharmaceutical, Huadong Medicine, Kangnuo Pharmaceutical-B, and others, which are positioned well within the TCM sector and are expected to benefit from policy support and market dynamics [35][43].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15]. - The report emphasizes the potential benefits for innovative drug companies due to the establishment of a collaborative innovation system and the promotion of new drug approvals [5][15]. - The report notes that the A-share pharmaceutical and biotechnology sector has shown a slight increase of 0.14% in the week from February 2 to February 6, 2026, outperforming the CSI 300 index by 1.47 percentage points [6][18]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a weekly high of 9323.49 and a low of 6876.88 [1]. Recent Market Performance - The A-share pharmaceutical sector outperformed the CSI 300 index and the ChiNext index during the week, ranking 15th among 31 sub-industries [6][18]. - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline [18]. Policy Developments - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of the TCM industry from 2026 to 2030, aiming to establish a collaborative development system and support leading TCM enterprises [4][15]. - The plan includes fostering a batch of innovative TCM drugs and enhancing the protection of intellectual property for traditional brands [5][16][17]. Investment Recommendations 1. **Innovative Drugs**: The report suggests that innovative drug companies remain a strong investment choice, with a focus on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio [7][21]. 2. **Medical Devices**: The medical device sector is expected to see a recovery in profits, with a focus on companies like Mindray and Kangji Medical, as the impact of centralized procurement diminishes [23][24]. 3. **Traditional Chinese Medicine**: Companies like Yiling Pharmaceutical and Tianjin Zhongxin Pharmaceutical are expected to benefit from policies supporting TCM and the clearing of high inventory levels [28][29][30]. 4. **AI in Healthcare**: Companies involved in AI applications in pharmaceuticals and diagnostics, such as iCarbonX and Huada Gene, are anticipated to benefit from advancements in AI technology [32][34].

Group 1: Development Goals and Framework - The State-owned Assets Supervision and Administration Commission (SASAC) has set the annual development goals centered on "two guarantees and two strives" for 2026, marking a shift towards quality and efficiency in state-owned enterprises (SOEs) [4] - The total assets of central enterprises have surpassed 95 trillion yuan, with R&D investment exceeding 1 trillion yuan for four consecutive years, indicating a focus on quality-driven growth [8] - The framework aims to guide state capital towards strategic security, public welfare, and emerging industries, providing a clear action plan for reform and development [4] Group 2: Industry Integration and Collaboration - In 2025, the restructuring of central enterprises will follow a dual-track approach, focusing on strategic formation of new central enterprises and multi-field professional integration [13] - The establishment of new central enterprises, such as China Yajiang Group and China Chang'an Automobile Group, aims to serve national macro strategies and enhance industry collaboration [14] - A total of 17 units signed agreements in key areas like artificial intelligence and new materials, creating a multi-party collaborative model involving central enterprises, private enterprises, and local governments [16] Group 3: Capital Investment and Fund Management - The total scale of the China Chengtong fund system reached 710 billion yuan, with 97.99% allocated to strategic emerging industries, demonstrating a strong focus on high-tech sectors [18] - The National Investment Group manages 61 funds with a total scale of 345.1 billion yuan, having invested in 1,249 projects and facilitated 293 companies going public [20] - The investment strategy emphasizes long-term support for innovative enterprises, with over two-thirds of funds directed towards private enterprises [20] Group 4: Resource Integration and Security - Central enterprises are undergoing intensive integration in key mineral sectors, such as iron ore and rare earths, to enhance resource control and pricing power [24] - The integration aims to create a closed-loop industry chain, improving domestic supply security and reducing reliance on imports [25] - This strategic move is seen as a vital step in ensuring national resource security and enhancing the global influence of China's mineral resources [24]

Group 1 - The Chinese medicine sector experienced a short-term surge, with Hansen Pharmaceutical achieving two consecutive trading limits, and companies such as Guhang Medicine, China Resources Sanjiu, Guangdong Wannianqing, Biotech Valley, and Dong'e Ejiao also seeing gains [1] - The Chinese Medicine ETF (560080) recorded a transaction volume of 78.1084 million yuan [1] - The recent rise in the sector was influenced by the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" [1]

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].